House Subcommittee to Examine Impact of Trump-Era Tariffs and Pricing Policies on Pharmaceutical Patents and Patient Access

The Trump administration’s April 2026 proclamation imposing 100% tariffs on patented pharmaceutical products has thrust pharmaceutical intellectual property into the center of a critical policy debate. Framed as a national security and supply chain measure, the tariffs specifically target patented drugs, directly engaging longstanding disputes among pharmaceutical companies, patient advocates, and intellectual property lawyers.

Simultaneously, an executive order signed in May 2025 established a Most-Favored-Nation (MFN) pricing policy aimed at aligning American drug prices with the lowest prices paid globally. This policy, exemplified by a recent deal with Regeneron, has heightened industry concerns that the commercial value of pharmaceutical patents is being eroded through executive action absent congressional approval.

The House Judiciary Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet will convene a hearing on June 3, 2026, to examine these intersecting pressures. The hearing will focus on the appropriate length and strength of drug patent protections and the implications for patients who may face higher costs or limited access to medicines.

This hearing arrives amid what analysts describe as a significant "patent cliff" in the pharmaceutical industry. Key patents on blockbuster drugs are expiring in 2026, enabling broader generic competition. For example, as of January 31, 2026, volume-limited licenses on lenalidomide ceased to be volume-limited, opening the market to generic entrants. These developments make the policy questions addressed in the hearing immediate and consequential, as the rules set now will influence future drug development.

In anticipation of the hearing, a Washington Times op-ed published on May 30, 2026, urged Congress not to weaken patent protections, warning that undermining post-approval pharmaceutical research could slow medical progress and harm patients. This commentary signals active engagement by pharmaceutical innovation advocates ahead of the subcommittee’s deliberations.

The Congressional Research Service (CRS) has highlighted legal complexities arising from the MFN pricing policy and the 100% tariffs. CRS noted potential conflicts between intellectual property rights—especially patents—and pricing controls, observing that it remains unclear whether tariffs might impede the establishment of MFN pricing.

These conflicting policies—tariffs that raise costs on imported patented drugs and MFN pricing that seeks to lower prices—create a live policy tension. Congress has yet to clarify the intellectual property framework governing pharmaceuticals in this context, making the June 3 hearing the first formal congressional forum to address these issues.

CRS also pointed to Section 1498 of U.S. law, which allows the federal government to issue compulsory licenses on patented inventions with reasonable compensation. This provision has surfaced periodically in drug pricing debates and is gaining renewed attention amid the administration’s aggressive stance on pharmaceutical costs.

The hearing will be chaired by Rep. Darrell Issa (R-CA), known for his strong support of intellectual property protections. Ranking Member Rep. Hank Johnson Jr. (D-GA) will lead the Democratic side. The subcommittee’s membership includes a diverse ideological mix, with members such as Reps. Jim Jordan, Zoe Lofgren, Ted Lieu, Jamie Raskin, and Thomas Massie, suggesting the hearing may reveal substantive bipartisan debate rather than predictable party-line divisions.

For patients, the stakes are direct: the duration and enforceability of pharmaceutical patents influence which drugs are developed, the timing of generic market entry, and ultimately drug prices at the pharmacy. DrugPatentWatch estimates that existing drug pricing provisions could reduce the federal deficit by $237 billion over ten years, representing a significant shift in value away from pharmaceutical companies. The industry counters that weakening patent protections diminishes returns on research and development, slowing the pipeline of new therapies.